Core Viewpoint - The stock of Weining Health (300253) has shown a significant increase of 5.10% on April 29, closing at 9.9 yuan, indicating strong market interest and potential investment opportunities in the AI healthcare sector [1]. Group 1: Stock Performance - On April 29, Weining Health's trading volume reached 1.1269 million shares, with a total transaction value of 1.115 billion yuan [1]. - The stock's turnover rate was 5.89%, reflecting active trading [1]. - The net inflow of main funds was 77.2564 million yuan, accounting for 6.93% of the total transaction value [1]. Group 2: Fund Holdings - The top ten public funds holding Weining Health include: - Nu'an Active Return Mixed A: 16.3698 million shares, newly entered the top ten [2]. - Great Wall Consumer Value Mixed A: 7.8036 million shares, newly entered the top ten [2]. - Guorong Rongsheng Leading Selection Mixed A: 6.9896 million shares, newly entered the top ten [2]. - A total of 15 public funds are reported to hold Weining Health shares, indicating strong institutional interest [2]. Group 3: Financing and Margin Trading - In the past five days, the net inflow of financing was 37.27 million yuan, with an increase in financing balance [1]. - The net inflow of securities lending was 17.8 million yuan, leading to an increase in securities lending balance [1]. Group 4: Analyst Ratings - Over the last 90 days, three institutions have provided ratings for Weining Health, with two giving a "buy" rating and one an "increase" rating [1]. - The average target price set by institutions in the past 90 days is 10.36 yuan [1].

Group 1 - The A-share market experienced a low opening but rebounded, with the artificial intelligence sector showing initial activity [1] - The Software ETF (159852) rose by 1.04% during trading, with a transaction volume exceeding 50 million yuan, and its constituent stocks like Weining Health increased by over 7% [1] - The Software ETF closely tracks the CSI Software Service Index, which includes 30 listed companies involved in software development and services, reflecting the overall performance of the software service industry [1] Group 2 - Alibaba announced the launch of its new model, Qwen3, which is the first "hybrid reasoning model" in China, integrating "fast thinking" and "slow thinking" into one model, significantly reducing costs [1] - Qwen3 outperformed global top models in various rankings, marking it as the strongest open-source model globally, and is considered a core technology product for Alibaba Cloud in the first half of the year [1] Group 3 - Zhongyuan Securities indicated that April is a peak period for annual and quarterly report disclosures, with the market shifting from expectation-driven to fundamental verification [2] - The market is expected to show characteristics of technology leadership, dividend defense, consumption recovery, and domestic demand-driven growth, suggesting structural investment opportunities [2] - Dongwu Securities highlighted that in a medium-term environment of "loose monetary policy + weak dollar," small-cap and growth styles are favored, with a focus on sectors like robotics, artificial intelligence, and domestic computing power [2]

本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 证券代码：300253 证券简称：卫宁健康 公告编号：2025-028 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于卫宁转债回售的公告 4、发行人资金到账日：2025 年 5 月 21 日 1、回售价格：100.281 元/张（含息、税） 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具 有强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（以下简称"公司"）的股票自 2025 年 3 月 16 日至 2025 年 4 月 28 日连续三十个交易日的收盘价格 低于当期"卫宁转债"转股价格 17.45 元/股的 70%，即 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-029 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于"卫宁转债"暂停转股的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会"证监许可〔2021〕311 号"文同意 注册的批复，卫宁健康科技集团股份有限公司（以下简称"公司"） 于 2021 年 3 月 16 日向不特定对象发行了 970.2650 万张可转换公司 债券，每张面值 100 元，发行总额 9.70265 亿元，期限为自发行之日 起六年，"卫宁转债"自 2021 年 9 月 22 日起可转换为公司股份，目 前处于转股期。 公司股票自 2025 年 3 月 16 日至 2025 年 4 月 28 日连续三十个交 易日的收盘价格低于当期"卫宁转债"转股价格 17.45 元/股的 70%， 即 12.22 元/股，且"卫宁转债"处于最后两个计息年度。根据公司 《创业板向不特定对象发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）的约定，"卫宁转债"的有 ...

法律意见 上海市广发律师事务所 关于卫宁健康科技集团股份有限公司 "卫宁转债"回售的 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市南泉北路 429 号泰康保险大厦 26 层 | 邮政编码：200120 上海市广发律师事务所 关于卫宁健康科技集团股份有限公司 "卫宁转债"回售的法律意见 致：卫宁健康科技集团股份有限公司 上海市广发律师事务所（以下简称"本所"）接受卫宁健康科技集团股份有 限公司（以下简称"公司"）的委托，依据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《可转换公 司债券管理办法》（以下简称"《管理办法》"）、《深圳证券交易所上市公司自律监 管指引第 15 号——可转换公司债券》（以下简称"《监管指引》"）现行有效的法 律、法规、规范性文件以及《卫宁健康科技集团股份有限公司创业板向不特定对 象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《卫宁健康科 技集团股份有限公司可转换公司债券持有人会 ...

Group 1: Financial Performance - The company's revenue and net profit declined significantly in 2024 due to deferred customer demand, delayed delivery acceptance, and the ongoing upgrade of the new product WiNEX, which has not yet converted into substantial revenue [17][11]. - In Q1 2025, the company reported a notable improvement in bidding amounts, indicating a potential recovery in market conditions [8][4]. - The company's gross profit margin has decreased primarily due to deferred customer demand and delays in the bidding process [14]. Group 2: Research and Development - The company reduced R&D expenses from CNY 333 million in 2023 to CNY 265 million in 2024, attributed to the maturation of the WiNEX product [5][9]. - In 2024, R&D investment was CNY 562 million, accounting for 20.21% of revenue, maintaining an average of over 20% in the past three years [12][7]. Group 3: Accounts Receivable and Debt Management - The company has seen a continuous increase in accounts receivable and contract assets, with government debt relief measures expected to improve collection rates [6][16]. - The company has a cautious approach to impairment loss provisions, reflecting the long payment cycles typical of public hospitals and health management departments [18]. Group 4: Market Position and Competition - The company believes it has a competitive edge in AI applications within the healthcare sector, having established an AI laboratory in 2017 and launched the WiNGPT product [15][3]. - The entry of major telecom operators into the healthcare information market is seen as a temporary challenge, with expectations of improvement in the future [10][6]. Group 5: Strategic Adjustments - The company has proactively abandoned low-quality hardware projects to focus on more profitable software and AI-related services [19][10]. - The company plans to enhance its market share and improve profitability through cost control and efficient project delivery [20][17].

Group 1: AI Redefining Healthcare - AI is transforming traditional medical practices, moving from manual operations to automated processes [3][5][9] - The shift from paper-based records to electronic medical records (EMR) and hospital information systems (HIS) is crucial for efficiency [7][23] - AI technologies like large language models and surgical robots enable goal-driven autonomous decision-making [9][19] Group 2: AI Collaboration with Healthcare Professionals - AI enhances collaborative decision-making between AI systems and doctors, improving diagnostic accuracy and patient care [13][19] - The integration of AI in clinical workflows allows for real-time interaction and decision support [16][21] - AI-driven tools facilitate the generation and quality control of medical records, ensuring compliance with standards [19][64] Group 3: Technological Advancements and Models - The latest model, WiNGPT2.8-32B, was developed starting January 2023, focusing on enhancing medical AI capabilities [39][40] - The model's training includes over 2.27 million instruction data points, improving its performance in medical contexts [44][48] - Advanced quantization techniques (AWQ and GPTQ) are employed to optimize model efficiency and performance [55] Group 4: Data Management and Security - The Model Context Protocol (MCP) standardizes interactions between large models and external data, enhancing data security [26][27] - AI systems are designed to minimize hallucinations and ensure the accuracy of generated medical information [25][66] - The integration of blockchain technology is proposed for maintaining transparency and accountability in AI-driven healthcare [23] Group 5: Practical Applications and Outcomes - AI applications have been successfully implemented in various clinical scenarios, including surgical assistance and patient management [72][73] - The use of AI in blood management and preoperative assessments has shown potential for improving patient outcomes [70][72] - Continuous feedback mechanisms are established to refine AI models based on user interactions and preferences [48][51]

Group 1: Financial Performance - In 2024, the company achieved a revenue of CNY 2.782 billion, a decrease of 12.05% year-on-year [2] - Net profit attributable to shareholders was CNY 88 million, down 75.45% year-on-year; net profit excluding non-recurring items was CNY 124 million, down 62.66% [2] - Core software and service revenue was CNY 2.152 billion, a decline of 9.25%; hardware revenue was CNY 293 million, down 38.57%; internet healthcare revenue was CNY 337 million, an increase of 7.83% [2] - In Q1 2025, revenue was CNY 345 million, a decrease of 30.24%; net profit attributable to shareholders was CNY 5.289 million, down 68.18% [3] Group 2: Cost Management and Cash Flow - The company implemented cost control measures, resulting in a combined decrease of 17.94% in sales, management, and R&D expenses [3] - Cash flow from operating activities reached CNY 408 million, a year-on-year increase of 120.53% [3] - In Q1 2025, the combined decrease in sales, management, and R&D expenses was 28.39% [3] Group 3: Product Development and AI Integration - The company focused on its core product WiNEX, with successful international projects like the Macau Concordia Hospital [3] - In 2024, R&D investment was CNY 562 million, accounting for 20.21% of revenue [3] - By March 2025, over 100 users had deployed the medical large model and AI applications [3] Group 4: Future Plans and Market Strategy - The company plans to expand its AI subscription model, having launched 9 AI subscription packages covering 18 scenarios [4] - The company aims to enhance customer engagement and increase the number of paying customers for AI services [4] - There are no current plans for share buybacks or increases, but future actions will be disclosed as necessary [5]

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

证券研究报告 卫宁健康 (300253 CH) 收入端受硬件及互联网医疗业务影响较大，费用整体管控良好 2025Q1 公司毛利率为 34.46%，同比提升 0.75pct，销售/管理/研发费率分 别为 14.96/9.23/14.85%，同比变动-0.09/0.57/0.67pct，费用管控良好。从 分业务来看：1）医疗卫生信息化收入 3.13 亿元，同比-23.44%，其中：核 心产品软件销售及技术服务收入 2.92 亿元，同比-18.08%，硬件销售收入 2147 万元，同比-75.65%；2）互联网医疗健康业务收入 3168 万元，同比 -36.77%。一季度公司收入受低毛利率的硬件及互联网医疗业务影响较大。 垂直大模型快速接入 DeepSeek，积极响应市场需求 一季度 DeepSeek R1 带来国内大模型应用的快速突破，公司积极响应客户 需求，发布 WiNEX Copilot 2.1 版本接入 DeepSeek。公司从数据工程、算 法及知识图谱等方面进行模型增强，以提高 DeepSeek 的专业性和可靠性， 使其更加适合于医疗严肃场景的应用。近期，公司新版本大模型与医护助手 在北京大学人民医院等三 ...